Rapport Therapeutics Inc RAPP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
-
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
-
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
-
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
Trading Information
- Previous Close Price
- $18.34
- Day Range
- $18.56–20.98
- 52-Week Range
- $16.55–28.08
- Bid/Ask
- $19.20 / $20.80
- Market Cap
- $760.79 Mil
- Volume/Avg
- 119,330 / 160,189
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.rapportrx.com
Comparables
Valuation
Metric
|
RAPP
|
CTNM
|
ARVN
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.26 | 2.01 | 2.85 |
Price/Sales | — | — | 11.83 |
Price/Cash Flow | — | — | — |
Price/Earnings
RAPP
CTNM
ARVN
Financial Strength
Metric
|
RAPP
|
CTNM
|
ARVN
|
---|---|---|---|
Quick Ratio | 41.52 | 58.48 | 3.57 |
Current Ratio | 42.08 | 58.92 | 3.62 |
Interest Coverage | — | — | — |
Quick Ratio
RAPP
CTNM
ARVN
Profitability
Metric
|
RAPP
|
CTNM
|
ARVN
|
---|---|---|---|
Return on Assets (Normalized) | −22.29% | −18.15% | −22.33% |
Return on Equity (Normalized) | −58.10% | −871.68% | −47.53% |
Return on Invested Capital (Normalized) | −62.59% | −892.99% | −54.26% |
Return on Assets
RAPP
CTNM
ARVN
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk AS ADR
NVO
| Sbbdrzkrq | Fqfxk | $512.4 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Gdjmvslv | Knfxlb | $117.5 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Csbtgkztm | Cjzlvl | $111.6 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Tzywwzl | Jlqqvz | $34.4 Bil | |||
argenx SE ADR
ARGX
| Lfctbyd | Gqpk | $31.7 Bil | |||
BioNTech SE ADR
BNTX
| Dsgnnjg | Xlflc | $29.2 Bil | |||
Moderna Inc
MRNA
| Rrtqsqznt | Mxln | $23.1 Bil | |||
United Therapeutics Corp
UTHR
| Ygpcbwtrr | Bsd | $15.8 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Cndytcyjm | Tjnrb | $13.2 Bil | |||
Incyte Corp
INCY
| Ytbdflg | Gfzcmxs | $13.0 Bil |